Related Experiment Video
Updated: Feb 11, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
Published on: October 9, 2014
Modulation of alternative splicing induced by paclitaxel in human lung cancer
Ziran Zhu1, Dan Chen2, Wenjing Zhang1
1Institute of Cancer Stem Cell & Radiotherapy Oncology Department of the Second Affiliated Hospital, Dalian Medical University, Dalian, 116044, China.
Abstract:
Paclitaxel is utilized as the first-line chemotherapeutic regimen for the majority of advanced non-small-cell lung carcinoma. However, whether paclitaxel could suppress cancer progression through modulating RNA alternative splicing remains largely unknown. Here, we demonstrated the effects of paclitaxel on cell proliferation inhibition, cell cycle arrest, and apoptosis. Mechanistically, paclitaxel leads to transcriptional alteration of networks involved in DNA replication and repair, chromosome segregation, chromatin silencing at rDNA, and mitosis at the transcriptional level. Moreover, paclitaxel regulates a number of cancer-associated RNA alternative splicing events, including genes involved in cellular response to DNA damage stimulus, preassembly of GPI anchor in ER membrane, transcription, and DNA repair. In particular, paclitaxel modulates the splicing of ECT2, a key factor involved in the regulation of cytokinesis. Briefly, paclitaxel favors the production of ECT2-S, the short splicing isoforms of ECT2, thereby inhibiting cancer cell proliferation. Our study provides mechanistic insights of paclitaxel on RNA alternative splicing regulation, thus to offer a potential novel route for paclitaxel to inhibit cancer progression.
Insights
Paclitaxel, a chemotherapy drug, inhibits non-small-cell lung cancer progression by altering RNA splicing. It promotes the production of short ECT2 splicing isoforms, suppressing cancer cell proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Paclitaxel is a primary chemotherapy for advanced non-small-cell lung carcinoma.
- The role of paclitaxel in regulating RNA alternative splicing for cancer suppression is not well understood.
Purpose of the Study:
- To investigate the effects of paclitaxel on cancer progression via RNA alternative splicing.
- To elucidate the molecular mechanisms underlying paclitaxel's anti-cancer activity.
Main Methods:
- Assessing paclitaxel's impact on cell proliferation, cell cycle arrest, and apoptosis.
- Analyzing transcriptional changes in response to paclitaxel.
- Identifying and characterizing paclitaxel-modulated RNA alternative splicing events.
Main Results:
- Paclitaxel inhibits cell proliferation, induces cell cycle arrest, and promotes apoptosis.
- Paclitaxel alters gene expression networks involved in DNA replication, repair, mitosis, and chromatin silencing.
- Paclitaxel specifically modulates splicing of ECT2, favoring the production of short isoforms (ECT2-S), which inhibits cancer cell proliferation.
Conclusions:
- Paclitaxel's anti-cancer effects are partly mediated by the regulation of RNA alternative splicing.
- Modulating RNA splicing, particularly of ECT2, offers a potential novel therapeutic strategy for paclitaxel in cancer treatment.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
RNA Splicing
Mechanisms of Retrovirus-induced Cancers
Lung Capacity
Null and Alternative Hypotheses
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...

